« Previous
Next »
Titles
- Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries2
- CMC postapproval manufacturing changes for specified biological products to be documented in annual reports2
- Comparing outcomes for dual eligible beneficiaries in integrated care: final report2
- Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards2
- Health insurance coverage and access to care among Latinos: recent trends and key challenges2
- Indian Health Service: actions needed to improve oversight of federal facilities' decision-making about the use of funds : report to Congressional addressees2
- Peripheral vascular atherectomy devices: premarket notification [510(k)] submissions : guidance for industry and Food and Drug Administration staff2
- Policy for temporary compounding of certain alcohol-based hand sanitizer products during the public health emergency: immediately in effect guidance for industry2
- Referencing approved drug products in ANDA submissions2
- Submission of plans for cigarette packages and cigarette advertisements (revised)2
- Temporary policy for preparation of certain alcohol-based hand sanitizer products during the public health emergency (COVID-19)2
- 340B Drug Discount Program: oversight of the Intersection with the Medicaid Drug Rebate Program needs improvement : report to Congressional requesters1
- 510(k) third party review program: guidance for industry, Food and Drug Administration staff, and third party review organizations1
- A comparison of brand-name drug prices among selected federal programs1
- A pathway to full integration of care for Medicare-Medicaid beneficiaries1
- A public option for health insurance in the nongroup marketplaces: key design considerations and implications1
- ACF cannot ensure that all child victims of abuse and neglect have court representation1
- ANDA submissions: amendments and requests for final approval to tentatively approved ANDAs1
- ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin1
- Access and use of electronic health information by individuals with cancer: 2017-20181